ArriVent outlines plans for $135M IPO in second biotech listing of 2024
ArriVent Biopharma, a Pennsylvania drugmaker developing a China-approved cancer treatment for the US and other geographies, plans to raise net proceeds of about $135 million in its Nasdaq listing.
It would be the second biotech IPO of the year after CG Oncology last week outlined its pitch for a $181 million Wall Street debut.
ArriVent plans on selling 8.33 million shares in its IPO and expects to price at $17 to $19 per share $AVBP, per a Monday morning SEC filing. Biotechs tend to go public within a week of penciling in their price range.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.